Calidi Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLDI research report →
Range $2 – $9
Price Chart
About the company
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents.
- CEO
- Eric E. Poma
- IPO
- 2021
- Employees
- 29
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on CLDI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.65M
- P/E
- -0.02
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.72
- EV/EBITDA
- 0.09
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -474.66%
- ROIC
- -644.90%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,651,000+0.0%
- Op Income
- $-20,240,000
- Net Income
- $-19,906,000+10.1%
- EPS
- $-95.20+83.3%
- OCF Growth
- -8.1%
- FCF Growth
- -8.6%
- 52W High
- $24.80
- 52W Low
- $0.46
- 50D MA
- $0.86
- 200D MA
- $3.28
- Beta
- 1.37
- RSI (14)
- 23
- Avg Volume
- 100.08K
No earnings-call transcripts are available for CLDI yet.
- Free Float
- 99.2%
- Shares Outstanding
- 3.45M
- Float Shares
- 3.42M
of shares held by institutions
29 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 34.73K | 0 |
| Northern Trust Corp | 17.76K | 0 |
| Tower Research Capital LLC (Trc) | 1.40K | 0 |
| Highbridge Capital Management LLC | 1.04K | 0 |
| Mercer Global Advisors Inc /Adv | 50 | ▲ 50 |
Held by 6 ETFs
Biggest fund positions in CLDI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 26 | Peoples George | other | 4,000 |
| Aug 17, 26 | Leftwich Scott | other | 4,000 |
| Aug 17, 26 | Stewart Alan R. | other | 4,000 |
| Aug 17, 26 | Jackson Andrew C. | other | 14,000 |
| Aug 17, 26 | Schoeneck James A | other | 5,000 |
| Aug 17, 26 | Poma Eric E | other | 32,000 |
| Aug 17, 26 | Fernandez Santidrian Antonio | other | 16,000 |
| Aug 17, 26 | Sanders Corazon (Corsee) D. | other | 6,000 |
| Jun 17, 26 | Sanders Corazon (Corsee) D. | other | 0 |
| Dec 12, 25 | Camaisa Allan | sell | 850 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLDI coverage
Recent articles, reports, and earnings notes.
No research on CLDI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLDI report →Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · Nov 13
Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
globenewswire.com · Oct 27
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
globenewswire.com · Oct 19
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
globenewswire.com · Sep 25
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
globenewswire.com · Sep 17
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 8
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · Aug 13
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
globenewswire.com · Jul 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.